Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dalantercept + Sorafenib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dalantercept | ACE-041|ALK1-Fc | ALK Inhibitor 26 | Dalantercept (ACE-041) is an ALK1 ligand trap composed of the ALK1 extracellular domain linked to the IgG Fc region, which binds to ALK1 ligands and prevents binding to the receptor, potentially leading to decreased tumor angiogenesis and growth and increased sensitivity to chemotherapeutic agents (PMID: 25708802, PMID: 26373572, PMID: 20124460, PMID: 30951193). | |
Sorafenib | Nexavar | BAY 43-9006 | CSF1R Inhibitor 26 FLT3 Inhibitor 58 KIT Inhibitor 52 PDGFR-beta Inhibitor 14 RAF Inhibitor (Pan) 21 RET Inhibitor 44 VEGFR2 Inhibitor 35 | Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is FDA approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02024087 | Phase Ib/II | Dalantercept + Sorafenib | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Completed | USA | 0 |